Deeplex®-MycTB, was used in a study published in The Lancet Infectious Diseases highlighting the spread of tuberculosis strains resistant to first-line antibiotics, not detected by current diagnostic tests.
The new Deeplex®-MycTB mycobacterial antibiotic resistance test , developed by GenoScreen, has been used by an international research team in a molecular epidemiology study published in The Lancet Infectious Diseases. This study highlights the spread of tuberculosis strains resistant to first-line antibiotics, not detected by actual international tests.
With 10 million new cases per year and 1.6 million deceases in 2017, tuberculosis is the most deadly infectious disease in the world . The number of new cases of multidrug-resistant tuberculosis emerging each year (estimated at 450,000 new cases in 2017 ) is a global public health problem.
On October 18th 2018, a study conducted in southern Africa, co-directed by Dr P. SUPPLY (CNRS/CHU/INSERM/ The University of Lille /Institut Pasteur de Lille), Dr B. de JONG (Institute of Tropical Medecine of Antwerp) and Dr E. ANDRÉ (Université Catholique de Louvain), has been published in The Lancet Infectious Diseases . It reveals that multidrug-resistant strains of tuberculosis are not detected by current diagnostic tests which cause ineffective treatment for patients, increased mortality and contagion, as well as an accumulation of additional resistance in the bacterial strains involved.
These results were achieved, mainly, credits to the innovative molecular test for predicting antibiotic resistance to this disease: the Deeplex®-MycTB test, developed by GenoScreen.